Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
June 04, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019, that...
Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
May 08, 2019 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
May 08, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
--Expands pipeline with 6th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE,...
Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
May 01, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2019,...
Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
April 08, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today stated that its previously announced...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2019,...
Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
March 28, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Interim analysis found statistically significant increase in dystrophin production as measured by western blot in casimersen-treated participants compared to baseline and placebo -- -- Based...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
March 25, 2019 07:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and...